<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084118</url>
  </required_header>
  <id_info>
    <org_study_id>LAN_POAF_01</org_study_id>
    <nct_id>NCT05084118</nct_id>
  </id_info>
  <brief_title>Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery</brief_title>
  <acronym>LANDI-POAF</acronym>
  <official_title>A Prospective, Randomized, Double- Blind, Placebo- Controlled Study to Evaluate the Efficacy of Landiolol Hydrochloride for Prevention of Atrial Fibrillation in Patients Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative atrial fibrillation (POAF) is the most common arrhythmia after cardiac surgery&#xD;
      with incidences ranging from 20% to 40% with the consequence of increasing mortality,&#xD;
      morbidity, and hospital length of stay, as well as increasing the costs to the health care&#xD;
      system. To prevent POAF the use of beta-blockers is suggested by the EACTA and ESC&#xD;
      guidelines. Despite the prophylactic use, the discontinuation of beta-blockers in the&#xD;
      perioperative period is a known risk factor that contributes to the occurrence of POAF. Due&#xD;
      to the short half time and the highly beta-1-selective properties of Landiolol, it could be&#xD;
      possible to initiate a betablocker for prevention in the immediate postoperative setting,&#xD;
      without adverse effects like hypotension or severe bradycardia as seen with other&#xD;
      betablockers like Metoprolol or even sometimes Esmolol.&#xD;
&#xD;
      Landiolol is already approved for the treatment of atrial tachycardias but is not yet&#xD;
      approved for the use of prevention of POAF. In multiple previous studies the preventive&#xD;
      potential of Landiolol in cardiac surgery could be proven in japanese study populations, with&#xD;
      limitations due to limited sample sizes. In these trials the use of low-dose Landiolol&#xD;
      effectively reduced the incidence of POAF without significant differences of increased side&#xD;
      effects or in the hemodynamic stability compared to the placebo or standard of care groups.&#xD;
&#xD;
      The primary objective of this prospective, double-blind, randomized, placebo-controlled phase&#xD;
      III trial is to prove that the postoperative application of low-dose Landiolol significantly&#xD;
      reduces the incidence of POAF without increased adverse events or hemodynamic instability&#xD;
      compared to the placebo group after cardiac surgery in a non-Asian population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point is a combined endpoint consisting of the occurrence of atrial fibrillation and mortality during the initial 72 hours period after surgery</measure>
    <time_frame>3 days</time_frame>
    <description>Death from any reason or the occurence of atrial in the holter ecg within 3 days after operation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence/ frequency of occurrence of atrial fibrillation during the first seven days after cardiac surgery</measure>
    <time_frame>7 days</time_frame>
    <description>The occurence of AF in the holter ecg in the 7 days after the operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic stability during treatment with IMP</measure>
    <time_frame>7 days</time_frame>
    <description>Hemodynamic stability assessed with the need for vasoactive medication in the two groups within 7 days after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>30 days</time_frame>
    <description>Postoperative length of stay in days in the icu</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of intensive respiratory and circulatory support</measure>
    <time_frame>30 days</time_frame>
    <description>Length of invasive ventilation in hours or need for circulatory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri- and postoperative mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Peri- and postoperative mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biomarkers as surrogate parameters for cardiac dysfunction</measure>
    <time_frame>30 days</time_frame>
    <description>Assessment of cardiac biomarkers to evaluate cardiac dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Assessment for cardiac injury, remodelling and fibrosis</measure>
    <time_frame>7 days</time_frame>
    <description>Biomarker assessment (TropT, CK, CK-MB, sST-2) for cardiac remodelling, fibrosis, apoptosis and ischemia reperfusion injury at time of start of the surgery, at ICU admission, 24 hours after ICU admission, 3 days and 7 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic assessment for left ventricular function</measure>
    <time_frame>7 days</time_frame>
    <description>Echocardiographic assessment for left ventricular systolic, diastolic and valvular function 7 days after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Postoperative Complications</condition>
  <arm_group>
    <arm_group_label>Landiolol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized patients receiving low dose landiolol after cardiac surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Randomized patients receiving 0,9% saline solution after cardiac surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Landiolol HCl</intervention_name>
    <description>continous 2mcg/kg/min low dose application of Landiolol HCl for 72 hours</description>
    <arm_group_label>Landiolol group</arm_group_label>
    <other_name>Rapibloc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>continous application of isotone saline solution for 72 hours</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Isotone saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≥ 18 years old&#xD;
&#xD;
          2. Written informed consent from patient&#xD;
&#xD;
          3. Patients are in sinus rhythm&#xD;
&#xD;
          4. Oral Betablocker in the patients long-term medication&#xD;
&#xD;
          5. One of the following cardiac surgical procedures which is planned on cardiopulmonary&#xD;
             bypass (CPB):&#xD;
&#xD;
               1. Single valve surgery&#xD;
&#xD;
               2. Single or multiple CABG procedures&#xD;
&#xD;
               3. Single valve surgery in combination with one or multiple coronary artery bypass&#xD;
                  grafts (CABGs)&#xD;
&#xD;
               4. Multiple valve surgery in combination with or without CABG&#xD;
&#xD;
               5. Single or multiple valve surgery in combination with ascending aorta procedure&#xD;
                  with or without additional CABG&#xD;
&#xD;
               6. Re-surgery of aortic valve, mitral valve, aortic arch or ascending aorta with or&#xD;
                  without CABG&#xD;
&#xD;
          6. Cardiac surgery is performed electively&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Bodyweight &gt; 101kg and/or BMI ≥ 40&#xD;
&#xD;
          2. Cardiac surgery is planned as minimally invasive procedure (e.g., without thoracotomy&#xD;
             or with lateral incision, minimal thoracotomy) or planned as off-pump surgery&#xD;
&#xD;
          3. Planned maze procedure, radiofrequency ablation, pulmonary vein ablation, resection of&#xD;
             the atrial appendix or atrial resections during the surgery&#xD;
&#xD;
          4. Sinus bradycardia (resting heart rate &lt; 50/min) at screening and before start of IMP&#xD;
             treatment&#xD;
&#xD;
          5. Second- or third-degree atrioventricular block at screening and before start of IMP&#xD;
             treatment&#xD;
&#xD;
          6. Clinical hypothyroidism or hyperthyroidism at screening&#xD;
&#xD;
          7. History of ventricular arrhythmia&#xD;
&#xD;
          8. Permanent atrial fibrillation or atrial fibrillation at time of screening and IMP&#xD;
             administration&#xD;
&#xD;
          9. Emergency cardiac surgery&#xD;
&#xD;
         10. Requiring inotropic, vasopressor or requiring ventilatory support at time of screening&#xD;
&#xD;
         11. Circulatory shock requiring mechanical circulatory support before initiation of study&#xD;
             medication&#xD;
&#xD;
         12. Distributive shock (cardiac index&gt;2.2 L/min with norepinephrine dose &gt; 0.3 µg/kg/min&#xD;
             to reach mean arterial pressure &gt; 65mmHg) before initiation of study medication&#xD;
&#xD;
         13. More than 5 units of RBC necessary to maintain a haemoglobin level &gt;8mg/dl at the end&#xD;
             of surgery&#xD;
&#xD;
         14. Prior cardiac surgery within the past 6 months&#xD;
&#xD;
         15. History of heart transplantation or planned heart transplantation&#xD;
&#xD;
         16. Any other disease or condition that is likely to interfere with the evaluation of the&#xD;
             study drug, outcome assessment or satisfactory conduct of the study:&#xD;
&#xD;
               1. Active infective endocarditis&#xD;
&#xD;
               2. Stroke or transient ischemic attack (TIA) within the last 6 months&#xD;
&#xD;
               3. Concomitant disease with a life expectancy of less than 6 months&#xD;
&#xD;
               4. Cardiopulmonary resuscitation within the last 4 weeks&#xD;
&#xD;
               5. Patients requiring renal replacement therapy&#xD;
&#xD;
         17. Active infection on current systemic antibiotics and/ or temperature greater than 38°C&#xD;
             at time of screening and before start of surgery&#xD;
&#xD;
         18. Haemoglobin &lt; 5 mmol/l (&lt; 8.06 g/dl)&#xD;
&#xD;
         19. Any systemic anti-cancer therapy within past 3 months&#xD;
&#xD;
         20. Patients with known hypersensitivity to any constituent of the IMP&#xD;
&#xD;
         21. General exclusion criteria:&#xD;
&#xD;
               1. Pregnant (in women of childbearing potential a urine or blood pregnancy test has&#xD;
                  to be performed) or breast-feeding women. Women with childbearing potential&#xD;
                  (defined as within two years of their last menstruation) not willing to practice&#xD;
                  appropriate contraceptive measures (e.g., implanon, injections, oral&#xD;
                  contraceptives, intrauterine devices, partner with vasectomy, abstinence) while&#xD;
                  participating in the trial&#xD;
&#xD;
               2. Participation in any interventional clinical trial within the last one-month&#xD;
                  prior randomization in this clinicaltrial (screening failures can be rescreened,&#xD;
                  if appropriate)&#xD;
&#xD;
               3. Alcohol, drug, or medication abuse&#xD;
&#xD;
               4. Employee at the study site, spouse/partner or relative of any study staff (e.g.,&#xD;
                  investigator, subinvestigators, or study nurse) or relationship to the sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Binder</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Division of Cardiothoracic and Vascular Anesthesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Binder</last_name>
    <phone>0043 1 40400 64100</phone>
    <email>andreas.binder@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Steinlechner</last_name>
    <phone>0043 1 40400 41850</phone>
    <email>barbara.steinlechner@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Binder, MD</last_name>
      <email>andreas.binder@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Steinlechner, Prof.</last_name>
      <email>barbara.steinlechner@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Andreas Binder</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>landiolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Landiolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

